Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 11/08/23
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian CancerBusiness Wire • 11/07/23
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient PopulationBusiness Wire • 11/06/23
Verastem Oncology Strengthens Executive Leadership Team with Key AppointmentsBusiness Wire • 10/26/23
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung CancerBusiness Wire • 10/14/23
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development SummitBusiness Wire • 09/28/23
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven CancersBusiness Wire • 08/28/23
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 08/08/23
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive OfficerBusiness Wire • 07/11/23
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 07/05/23
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 06/16/23
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 06/15/23
Verastem Stock Is Outperforming 92% Of The Market — And It Just SurgedInvestors Business Daily • 06/15/23
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and DefactinibBusiness Wire • 05/25/23
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 05/09/23